{"id":"NCT00663702","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase IIIB Switching From Intravenous to Subcutaneous Study","officialTitle":"A Phase 3B Multi-center Open-Label Study to Evaluate the Safety of Abatacept in Subjects Who Switch From Intravenous to Subcutaneous Abatacept Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2009-12","completion":"2012-01","firstPosted":"2008-04-22","resultsPosted":"2012-03-26","lastUpdate":"2015-03-09"},"enrollment":123,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"Abatacept","otherNames":["Orencia","BMS-188667"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether switching to subcutaneous administration of abatacept will be safe in participants with rheumatoid arthritis who previously received long-term therapy with intravenous abatacept","primaryOutcome":{"measure":"Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), AEs Leading to Discontinuation, and AEs of Interest (AEIs) at Day 85","timeFrame":"Day 1 (Baseline) through Day 85","effectByArm":[{"arm":"Subcutaneous Abatacept, 125 mg","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":5},"locations":{"siteCount":30,"countries":["United States","Canada","Mexico"]},"refs":{"pmids":["27229685"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":123},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Cough","Bronchitis"]}}